| Model Number |
305C25 |
| Medical Device Problem Codes |
Insufficient Device Problem Information (3190); Device Stenosis (4066); Intravalvular regurgitation (4068)
|
| Health Effect - Clinical Codes |
Aortic Valve Stenosis (1717); Calcium Deposits/Calcification (1758); Aortic Valve Insufficiency/ Regurgitation (4450)
|
| Date of Event |
08/20/2025
|
|
Type of Reportable Event
|
Serious Injury
|
|
Additional Manufacturer Narrative
|
|
Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
| |
|
Event or Problem Description
|
|
Medtronic received information that 15 years and 3 months post implant of this mosaic aortic valve, the patient is being evaluated for a transcatheter valve-in-valve replacement.The reason for evaluation was not reported.Evidence of calcification in the left ventricular outflow tract (lvot) under the left coronary cusp (lcc), the right coronary cusp (rcc) and non-coronary cusp (ncc).No intervention or adverse patient effects were reported.
|
| |
|
Additional Manufacturer Narrative
|
|
B1, b5 and imf (annex f) codes updated.Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
| |
|
Event or Problem Description
|
|
Additional information was received that on (b)(6) 2025, a 26mm transcatheter valve was implanted valve-in-valve.No additional adverse patients effects were reported.
|
| |
|
Event or Problem Description
|
|
Additional information received reported that the reason for intervention was moderate - severe aortic stenosis (as) and moderate - severe aortic regurgitation (ar).No additional adverse patient's effects were reported.
|
| |
|
Additional Manufacturer Narrative
|
|
Sections updated: b.1, b.2, b.5, g.6, h.2, h.6.Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
| |
|
Search Alerts/Recalls
|